The increasing number of laboratories offering molecular genetic analysis of the CFTR gene and the growing use of commercial kits strengthen the need for an update of previous best practice guidelines (published in 2000). The importance of organizing regional or national laboratory networks, to provide both primary and comprehensive CFTR mutation screening, is stressed. Current guidelines focus on strategies for dealing with increasingly complex situations of CFTR testing. Diagnostic flow charts now include testing in CFTR-related disorders and in fetal bowel anomalies. Emphasis is also placed on the need to consider ethnic or geographic origins of patients and individuals, on basic principles of risk calculation and on the importance of providing accurate laboratory reports. Finally, classification of CFTR mutations is reviewed, with regard to their relevance to pathogenicity and to genetic counselling.
Introduction
Cystic fibrosis transmembrane conductance regulator (CFTR) gene studies represent one of the most frequent genetic analyses routinely performed worldwide. Such tests are carried out in various situations, including molecular diagnosis of cystic fibrosis (CF), prenatal diagnosis, and carrier testing. CF is primarily a clinical diagnosis based on consensus clinical and laboratory criteria. 1 Detailed phenotypic characteristics can be found elsewhere. 1 -5 Laboratory criteria include a positive sweat test (chloride value above 60 mEq/l), and/or presence of two CF-causing mutations (in trans), and/or abnormal values of electrophysiological measurements, that is, nasal potential difference and rectal chloride transport. More than 1500 sequence variations have been reported in the CFTR gene, often with geographic or ethnic variations in frequency 6 -8 and which are found in both CF and related phenotypes, named CFTR-related disorders (CFTR-RD). These are clinical entities associated with CFTR dysfunction but where the diagnosis of CF cannot be unambiguously established; 1 for example, congenital bilateral absence of vas deferens (CBAVD) 9 -13 disseminated bronchiectasis, 14, 15 chronic pancreatitis, 16, 17 or chronic rhinosinusitis. 18, 19 CFTR gene analyses are performed in specialist clinical molecular genetics laboratories closely associated with clinical genetic services or research facilities, and also in private laboratories; lists of European laboratories offering CFTR genetic testing are available at www.orpha.net or at www.eurogentest.org/web/qa/basic.xhtml. A good knowledge of CFTR diseases and their molecular pathology is required when choosing tools and strategies and when interpreting results. Genetic testing should only be performed in the context of appropriate genetic counselling and laboratories should work in close association with clinical geneticists and reference laboratories to ensure that pertinent tests are performed and proper information is provided to the patients. The need for organization of regional or national networks of laboratories is thus emphasized.
Previous recommendations for quality improvement in CF genetic analysis were published in 2000 under the aegis of the European Concerted Action on Cystic Fibrosis. 20 These recommendations have been widely implemented in the framework of national or regional networks of diagnostics laboratories. However, an update has become necessary since many more laboratories are now offering CFTR genetic testing; the number of and indications for referrals have increased, in particular in the area of male infertility; knowledge of CFTR molecular pathology has evolved; and laboratory practice has changed, notably in the methods used. Moreover, 10 years experience of European external quality assessment (EQA) shows that, although there has been steady improvement in the quality of CFTR testing, many issues still need to be addressed. In addition, a number of initiatives have been taken, aiming at international consensus and the development of best practice guidelines for molecular genetic services either in general terms, for example, by the OECD 21 or the Network of Excellence 'EuroGentest'
(www.eurogentest.org), or specifically for CF such as the Concerted Action 'EuroCareCF' (www.eurocarecf.eu) and the Neonatal Screening Working Group of the European Cystic Fibrosis Society (www.ecfs.eu). 22 Invaluable efforts have also been made by American colleagues to edit standards and guidelines for CFTR testing, in particular through the American College of Medical Genetics (www.acmg.net) and the American College of Obstetricians and Gynecologists (www.acog.org), and Cystic Fibrosis Foundation tasks (www.cff.org) 23 -25 Harmonization and consensus among these initiatives are critical. The present guidelines are the result of a conference held in Manchester, 25 -26 October 2006 , with the partnership of EuroGentest and the CF Network (www.cfnetwork.be). This meeting involved 15 experts in the field of CF and molecular diagnostics, from 11 European countries. The main purpose was to provide molecular geneticists involved in CFTR genetic testing with recommendations for testing and reporting of molecular genetic analysis. Reference laboratories are encouraged to discuss, validate, and facilitate implementation of these recommendations within their national or regional networks.
Methods for CFTR gene analysis
Methods for CFTR mutation detection CFTR molecular testing mainly relies on direct gene analysis procedures, that is, the detection of diseasecausing mutations, which are based on our knowledge of CFTR molecular pathology and on the availability of molecular tools for detecting mutations. A wide range of techniques is used to identify CFTR gene sequence variations and there is no gold standard for routine testing. All available methods require skill and experience to perform and interpret. There is no standard or preferred method(s), but laboratories should be aware of the limitations of their chosen method and should know which mutations are not identified, whether the techniques are commercially available or developed within the laboratory. This means that individual laboratories should choose a method, which is suited to their experience, workload, and scope of testing.
Methods used in CFTR testing can be divided into two groups: those targeted at known mutations (ie, testing DNA samples for the presence or absence of specific mutation(s)) and scanning methods (ie, screening samples for any deviation from the standard sequence). These now include searching for large unknown CFTR rearrangements, including large deletions, insertions, and duplications, by semiquantitative PCR experiments, that is, multiplex ligation-dependant probe amplification (MLPA) or quantitative fluorescent multiplex PCR. 26 -28 Such rearrangements, which can escape detection using conventional amplification assays, have been shown to occur in up to 2% of alleles in CF patients 26 -30 and 1% in CBAVD patients. 13 The features of the methods currently applied are summarized in Table 1 . The list is not exhaustive and will need regular updates with the advent of new validated technologies, such as high-resolution melting curve analysis (HRMCA). 31 Furthermore, commercial assays also evolve to meet the users' requests. The CF Network provides an annual overview of mutations tested by commercial assays used by the participants of its EQA scheme (www.cfnetwork.be). Even though commercial kits may be CE-marked in vitro diagnostic devices (IVDD), assay performance should always be verified by laboratories before diagnostic use. The combined use of all these techniques cannot guarantee detection of the two disease-causing mutations (in trans -ie, on both parental alleles) in all patients; 1 -5% of alleles remain undetermined in CF patients with the classical form and even more in patients with atypical presentations. Moreover, the percentage of undetected mutations increases from northern to southern European populations. CFTR mutations may 34 However, the diagnostic utility of ENaC testing in routine practice has not been determined.
Analysis of CFTR microsatellite markers
Besides direct gene analysis procedures, analysis of polymorphic CFTR markers 35 -39 may be helpful in particular situations ( Table 2) . Although recombination within the CFTR gene is very rare, the use of multiple microsatellite markers is recommended for family studies.
Guidelines for CFTR testing
Organization of CFTR testing provision The extensive heterogeneity in the distribution of CFTR gene mutations in European populations 6 -8 makes the goal of a mutation detection rate of over 95% very hard to achieve, except with a combination of scanning methods. Efforts should be made to provide testing of reasonably high sensitivity and to detect all CF-causing mutations with a frequency above 1% in the local population. However, because a number of situations require additional testing beyond a local panel, and because many laboratories now exclusively use a commercial kit, collaborative networks of laboratories are critical. Laboratories should be aware of the fact that companies usually optimize their panels for American and/or Western European populations. As a consequence, the sensitivity of the test varies between populations and may be low in certain regions, notably Central, Southern and Eastern Europe. Practical organization of laboratories at two levels of expertize should ideally be agreed within a particular region or country. Table 3 summarizes criteria for laboratories of 'level 1' (screening) and 'level 2' (reference) laboratories. Laboratories should be aware of the actual or estimated mutation detection rate in any given situation and determine when rare or specific mutations should be sought, possibly in a 'level 2' laboratory.
Pretest requirements
The quality of the final result depends not only on the laboratory procedures themselves, but also on the referral information, which must be sufficient to allow correct selection of the precise test. Questionnaires to this end can be made available by laboratories. Informed consent should be obtained in compliance with applicable legal, ethical, and professional standards. Pretest and post-test counselling, proportionate to the significance of test results, should be available to individuals and their relatives. In the case of family studies, no information regarding carrier status should be communicated to the third parties without the consent of the individual tested.
Indications for CFTR testing Appropriate strategies and decision procedures for diagnostic testing in different situations and for carrier testing are presented as flow charts or discussed in the following sections.
Indications for CFTR testing
Diagnostic testing in typical CF presentation ( Specific situations can be handled individually, beyond the suggested flow charts. In particularly difficult situations, it is essential that the diagnostic strategies are shared with the referring clinician and/or a 'level 2' laboratory. As in the previous guidelines, diagnostic testing should be considered within the context of a diagnostic algorithm, as published elsewhere. 41 General guidance for reading flow charts In all instances in the flow charts, the search for frequent CF-causing mutations refers to the screening of a common panel as the first-step method. The respective panel may vary between laboratories because of the requirement of the local population, although, in most cases, the 'basic' panel may be determined by one of the available commercial assays.
As in all other autosomal recessive diseases, identification of mutation(s) on both parental alleles is required to confirm the diagnosis. Homozygous and compound heterozygous status should thus be confirmed by studying the parents. Moreover, the assignment of correct parental Figure 1 Diagnostic testing in typical CF presentation. The diagnostic algorithm applies irrespective of the age of the CF patient, from newborn screening to late diagnosis in adults. While the diagnosis of CF can be based on the presence of one or more characteristic phenotypic features, 1 a classical or typical clinical CF presentation mainly associates respiratory symptoms with pulmonary obstruction and infections, exocrine pancreatic dysfunction, and infertility in adult males, along with sweat chloride concentrations above 60 mEq/l that provide an evidence of a CFTR defect. IRT, immunoreactive trypsinaemia; NPD, nasal potential difference; ICM, intestinal chloride measurement.
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De novo mutations have been described but are exceptionally rare. 42, 43 If the mutations are not found in the parents, laboratories should be aware of the possibility of non-paternity and sample mix-up. Uniparental disomy of chromosome 7 is also extremely rare and usually associated with atypical and/or syndromic presentation, including growth retardation or overgrowth.
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Particular comments and recommendations for specific indications Male infertility with CBAVD In male infertility due to obstructive azoospermia, documented cases with CBAVD with strict diagnosis criteria (List below) have been shown to be commonly linked to CFTR mutations ( Figure 3) . CBAVD is the best known CFTR-RD. Extensive studies have shown that approximately 80% of patients with isolated CBAVD carry two CFTR mutations, usually in compound heterozygosity.
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Diagnostic criteria for CFTR-related CBAVD Azoospermia Low seminal fluid volume (o2.0 ml) Typical biochemical features: pH o7.2, absent or decreased fructose and a1 -4 glucosidase (markers of properly functioning seminal vesicles and epididymis, respectively) Absence of palpable vas deferens On transrectal ultrasound: absence of the intra-abdominal tract of the vas deferens, globus major, and different degrees of hypoplasia of the seminal vesicles. These anomalies may also be confirmed at surgical sperm retrieval. Normal plasma follicle-stimulating hormone (FSH), luteinizing hormone (LH), and testosterone levels
Whether patients with unilateral absence of vas deferens (CUAVD) or other renal -ureteral anomalies have an increased risk of carrying CFTR mutations remains controversial. 11, 48, 49 Additional data should be provided to determine the utility of CFTR testing in these situations.
Other CFTR-RD in adults Chronic pancreatitis, disseminated bronchiectasis, or atypical chronic rhinosinusitis have been associated with an increased frequency of CFTR mutations. Suspicion of CF in fetuses with bowel hyperechogenicity and/or loop dilatation Fetal bowel anomalies are most often observed during the ultrasound examinations in the second trimester of pregnancy (Figure 4) . They can be due to CF or other disease conditions or may be not associated with disease. Diagnostic investigations should therefore include searching for frequent CFTR mutations, fetal karyotyping, and screening for viral infections (in particular cytomegalovirus). 51 However, depending on national regulation and maximum term for termination of pregnancy, this situation may not lead to diagnostic investigations. While the overall risk of CF varies between studies, 52 -56 a large French collaborative study of 641 pregnancies presenting varied fetal bowel anomalies, determined the risk of CF as 3%. 54 Significant anomalies were grade III hyperechogenicity (ie, where the ultrasound echogenicity of the fetal abdomen was equal to the surrounding bone tissue) and loop dilatation.
Prenatal diagnosis Laboratories that perform PND should fulfil all requirements of 'level 1' laboratories (Table 3) . PND should be performed on request, following genetic counselling, and can be offered to: (1) Figure 5 Cascade CF carrier testing. The purpose of carrier testing is to provide individuals with reproductive options and allow informed choices.
Carrier testing in children should be deferred until the child can understand the issue and request the test in person. 40 a Reporting a negative result for familial mutation testing should be carried out cautiously if the mutation has been identified in another laboratory, unless a copy of the original report is available to the laboratory in charge of the test. Test for the familial mutation may be performed in the same step as for the frequent mutations.
c In case the familial mutation is known and both couple members are tested in the same time, if the relative unexpectedly tests 'negative' and the partner tests 'positive', especially for the familial CF mutation, it is recommended to confirm the results, possibly with new samples and/or using microsatellite assays.
Best practice guidelines for CFTR testing E Dequeker et al in the laboratory, and duplicates processed independently. PND reports should routinely be issued within 1 week of receiving the sample.
In some European centres, preimplantation genetic diagnosis (PGD) can be offered for at-risk couples as an alternative to PND. PGD should be performed according to the highest quality standards, with respect to local ethical, and legal requirements. Technical and medical procedures should be at least in agreement with the guidelines of the European Society of Human Reproduction and Embryology (ESHRE). 57 CF carrier screening in individuals without a family history Attitudes regarding carrier screening in the general population differ between individual countries. In the United States, preconceptional carrier screening is recommended 23 and performed using a consensus panel of CF-causing mutations, 25 whereas in Europe, the situation is much more heterogeneous: 58 population
screening was implemented in a number of different regional or national programmes, especially as prenatal screening, 59 -61 while it is not recommended in other countries. Despite the absence of European consensus for recommendation of CF screening in couples seeking preconceptional counselling, appropriate information about the disease and its genetic aspects, as well as the possibility and the limits of testing, should be provided on request.
CF carrier testing in infertile couples (non-CBAVD couples) Recommendation of CF screening in the case of in vitro fertilization (IVF) procedures 62 is not widely shared among European Genetics societies, as the risk of carrying a CF mutation is not significantly higher than that of the general population. However, this issue may be discussed with couples in a genetic counselling session before IVF.
Consideration of ethnic/geographic origins
In addition to the screen for frequent mutations, a complementary panel may be required to test population-specific mutations with a frequency above 1%. Knowledge of the ethnic or geographic origins of patients and their parents and grandparents is therefore important to determine the analysis to be performed. These studies should be considered in the following situations: (1) carrier testing, especially in partners of CF carriers or patients; (2) fetal bowel anomalies when no mutation of the basic panel is found but where consanguinity is documented, or in case of decreased intestinal enzyme activities in amniotic fluid. Where a parent is found to be a CF carrier, knowledge of the other parent's origin could help to target the exons to be first analysed for searching a potential second CF mutation.
Data on disease and carrier frequencies as well as on mutation frequencies in various populations are available in the latest WHO report 63 and in the literature.
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Guidelines for interpretation
Consideration on the classification of CFTR mutations CFTR sequence variants are associated with a broad range of phenotypes, mainly due to their varied effects on protein synthesis and function. Many clinicians and laboratories use 'mutation' and 'polymorphism' to indicate 'disease-causing' and 'neutral/ benign' variants, respectively, a practice that is incorrect and should be avoided. The terms mutation and 'sequence variant or alteration' are formally synonymous and do not denote any functional consequence or disease association, whereas polymorphism formally designates a variant with an allelic frequency over 1% in the general population irrespective of any clinical significance. It is essential for laboratories to make clear whether a detected variant is predicted to cause CF, to have a severe or moderate effect, to be associated with CFTR-RD, or to be phenotypically neutral.
The classification of CFTR gene mutations according to their functional effects on CFTR protein production and function, 64, 65 based on functional studies, has been widely used in the scientific literature. However, only a limited number of mutations have been studied and many CFTR mutations have different functional consequences and cannot be assigned to one particular class. In other respects, it should be noted that the categorization of CFTR mutations is not predictive of individual outcomes. CFTR genotype/phenotype correlations may be used at a population level to determine associations, but should not be used to indicate prognosis in individual patients. A classification of CFTR gene mutations, based on their potential for causing disease and their implication for genetic counselling, that is, whether they should be considered for PND and cascade carrier testing, may be used instead. A number of criteria are taken into account to determine which effect a sequence variation may have (Lists below). 1, 66, 67 Mutations may be clustered in four groups (Table 4) Only mutations that cause CF should be considered for carrier testing and PND provided both couple members are carriers. Some CF mutations may be associated with a wide phenotypic spectrum and discussion should take into account these generally milder phenotypes. As a precaution, mutations of unproven or uncertain clinical relevance may be considered as potentially CF causing. However, a thorough examination of the CFTR gene should be performed to search for complex alleles whenever variants of unpredictable effect are identified.
Because of the interplay of the CFTR genotype and other genetic or environmental factors, there may be overlapping of groups.
Criteria for mutations predicted to cause CF: (1) Criteria of high degree of certainty:
Cause a change in the amino-acid sequence that severely affects CFTR synthesis and/or function Introduce a premature termination signal (insertion, deletion, or nonsense) Alter the invariant nucleotides GT/AG of intron splice sites Delete one or more exons (2) Criteria of a lower degree of certainty:
Cause a novel amino-acid sequence that does not occur in the normal CFTR gene from at least 100 carriers of CF mutations from the patient's ethnic group Change a highly evolutionarily conserved amino-acid residue Create a novel/cryptic splice site Similar sequence variations are found in other genes of the ATP-Binding Cassette family
Indirect evidence that a CFTR mutation does not cause CF:
The other allele is carrying a well-known CF-causing mutation in a clearly asymptomatic individual A silent exonic mutation, without a priori splicing modification An intronic mutation outside the known consensus sites and which does not create a predicted splicing site Frequency in the general population is higher than in the CF population. 68 Novel sequence changes may be subjected to the analysis by computer algorithms to assist in determining their potential pathogenicity. Such programmes include SIFT, 69 Polyphen, 70 and Splice site prediction.
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Comments on particular sequence variations T(5) The (T)5 splicing variant of the intron 8 acceptor splice site is not considered a CF-causing mutation but CFTR-RD-associated. It should not, therefore, be tested in the context of carrier testing in relatives, partners of carriers and of patients, and in the cases of fetal bowel anomalies. There are three common alleles at the polypyrimidine tract of the intron 8 acceptor splice site: (T)5, (T)7, and (T)9 (5, 7, and 9 thymidines, respectively). The lower the number of thymidines, the lower the efficiency of exon 9 splicing. The extent of splicing is further affected by the number of adjacent (TG) repeats, thereby modulating the disease penetrance of the (T)5 variant:
72,73 the higher the number of (TG) repeats, the lower the efficiency of splicing. A (T)5 variant can either be associated with (TG)11, (TG)12, (TG)13, and rarely (TG)15 repeats. 74 When (T)5 is found in diagnostic testing, for example, for CBAVD or atypical presentation, determination of Figure 3) . When (T)5 is found in a patient with typical CF or in the context of neonatal screening, whatever the (TG) length, other mutations in cis (forming complex alleles) should be sought.
I148T Was initially described as a frequent CF-causing mutation. However, recent data have provided evidence that it is not CF-causing in itself. 75 -77 In CF patients, other mutations in cis should be sought, in particular 3199del6 (located in exon 17a). I148T should not be routinely screened for and is currently being removed from the panels of commercial assays. PðCjno mutÞ¼ PðCÞÂPðno mutjCÞ PðCÞÂPðno mutjCÞþPðno CÞÂPðno mutjno CÞ P: probability; C: carrier; no mut: no mutation; P(C| no mut): probability that the individual is a carrier, provided that he tested negative for the investigated mutations.
Many scenarios for CF risk calculations have recently been assessed by Ogino et al; 79 -81 other examples were presented in the previous version of these recommendations. 20 In many situations where prior probabilities are in clearly different ranges (for instance 1/25 of being a carrier and 24/25 of being non-carrier), risk calculations can be performed by using simplified formulae, 20 which consist in assimilating the overall probability of having a negative result (denominator of the above formula) to 1 (100%). The simplified formulae are easy to use and the error, compared with the mathematically more correct ones, is often very small. This error might be even smaller than the error of the input parameter for CF prevalence (Table 5 , Example 1). Product of prior and conditional probability. f Joint probability for that hypothesis divided by the sum of all joint probabilities (Bayesian analysis). This is the probability that the individual is a carrier, given that he tested 'negative'. g Product of prior and conditional probability (joint probability), which is a simplified calculation.
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In other cases where prior probabilities of both hypotheses are of similar magnitude, it is necessary to use Bayesian analysis instead of simplified formulae, since the mathematically correct result differs substantially and may lead to erroneous conclusions. In Example 2 in Table 5 , both hypotheses of being and not being a carrier have a prior probability of approximately 1 2 ; the result obtained by the simplified calculations is almost in the range of the general carrier frequency (1/20 versus 1/25), whereas the mathematically correct result (E1/11) yields a much higher carrier probability. Carrier testing for the partner should clearly be offered in the case of an individual with a 1/11 carrier probability, but this is less evident if the carrier probability is approximately the same as in the general population. The simplified posterior probability in this example would thus be, misleadingly, 
Reporting the results
Genetic test results should be communicated to the referring physician or genetic professional and to any physician designated by the patient. Reports of the test results should be issued in a standardized form, clearly intelligible to the non-specialist. Items that should be included in a standard molecular analysis laboratory report are listed in the list below. Reports should, as far as possible, answer the question asked by the clinician. It is suggested that important remarks are highlighted in bold, for example, the patient's genotype and clinical implications, whereas technical details may be written in smaller characters or presented in footnotes. To avoid confusion, it is suggested that sequence variations with no clinical consequences (for example, 1540A4G (M470V)) are not reported. If it is not clear whether the identified mutation is neutral or putatively disease causing, the interpretation should include a statement such as: 'mutation of unproven or uncertain clinical relevance'. It must be recognized that an individual's negative result does not exclude the presence of undetected CFTR mutations. Along with the report, a pedigree with the genotype information may be included, if applicable (eg, linkage study).
In general, the laboratory should not directly report results to the patient and should ensure that the clinician reporting to the patient has a full understanding of the results and their underlying clinical meaning.
No information regarding the mutation analysis results should be communicated to the third parties without the consent of the individual tested or his/her representative.
Content of a standard report for CFTR gene molecular analysis
Laboratory that issues the report: name and address Nomenclature for designation of mutations A systematic common nomenclature is essential for the description of mutations in reports, publications, and mutation databases. It helps clinical geneticists to provide accurate information for diagnosis and genetic counselling, and researchers to determine whether a specific mutation has been described as well as to identify patients with the same mutations.
Laboratories must take care to report mutations in a way that is both understandable and unambiguous. Most laboratories currently use the traditional nomenclature, according to the CF Mutation Database. 8 Human Genome Variation Society (HGVS) nomenclature 82 may be more precise in some situations but can also lead to confusion. For example, HGVS defines the 'A' of the translation initiation codon as þ 1 (traditionally þ 133)
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The CF consortium intends to list both the traditional and HGVS nomenclature in parallel in its CF Mutation Database (J Zielenski, personal communication 2007).
Conclusions
The recommendations described here are an attempt to improve the quality of CFTR mutation testing and promote this as a model for improvement of the overall quality of genetic testing. Harmonization of procedures and the creation of collaborative networks of laboratories should assure a high level of quality of genetic testing to the benefit of patients, families, and the general population. Education of the laboratory staff, clinicians, and all individuals concerned with all aspects of CF and related CFTR pathology should be encouraged. Despite possible unequal access to health care between countries or regions, exchanges and discussions at regional, national, or supranational levels, based on these guidelines, should further help laboratories to obtain facilities and equipment from their authorities. Since the field is steadily evolving in terms of knowledge of the molecular pathology and of genotype -phenotype correlations and due to continuous improvement of diagnostic tools and procedures, these guidelines need to be updated on a regular basis.
